Literature DB >> 20620967

Diagnostic issues in chronic lymphocytic leukaemia (CLL).

Estella Matutes1, Ayoma Attygalle, Andrew Wotherspoon, Daniel Catovsky.   

Abstract

The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features. Morphology and immunophenotype are the initial diagnostic investigations. In atypical cases, these tests should be complemented with molecular genetics and/or histology to exclude other B-cell disorders of small lymphocytes. Morphologically, CLL can be classified into typical and atypical. Immunophenotyping is the only method that can establish or confirm the diagnosis as CLL lymphocytes have a distinct immunophenotypic signature. A scoring system compounding the results with a set of markers allows firming up the diagnosis. Other immunological markers such as CD38 and ZAP-70 have an important prognostic impact. Fluorescence in situ hybridization (FISH) analysis, chiefly by detecting 17p (TP53 locus) and 11q (ATM) deletions and mutational status of the IgVH gene, also provides prognostic information and may determine the type of therapy. In atypical CLL, histology and/or molecular genetics may be required to exclude other B-cell disorders. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20620967     DOI: 10.1016/j.beha.2010.01.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  8 in total

1.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Authors:  S Jeromin; S Weissmann; C Haferlach; F Dicker; K Bayer; V Grossmann; T Alpermann; A Roller; A Kohlmann; T Haferlach; W Kern; S Schnittger
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

Review 2.  The biology behind PI3K inhibition in chronic lymphocytic leukaemia.

Authors:  Valentín Ortiz-Maldonado; Marcial García-Morillo; Julio Delgado
Journal:  Ther Adv Hematol       Date:  2015-02

3.  Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study.

Authors:  Milena Todorovic; Bela Balint; Bosko Andjelic; Dejana Stanisavljevic; Nada Kraguljac Kurtovic; Ziv Radisavljevic; Biljana Mihaljevic
Journal:  Med Oncol       Date:  2011-12-15       Impact factor: 3.064

4.  The potential differential diagnosis value and clinical significance of CD35 expression in B-chronic lymphoproliferative disorders.

Authors:  Yu Shi; Lu Liu; Hui Yang; Xiao Chen; Yan Wang; Sishu Zhao; Huimin Jin; Yujie Wu
Journal:  Ann Transl Med       Date:  2021-07

5.  The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia.

Authors:  Eahsan Rasul; Daniel Salamon; Noemi Nagy; Benjamin Leveau; Ferenc Banati; Kalman Szenthe; Anita Koroknai; Janos Minarovits; George Klein; Eva Klein
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

Review 6.  Leptomeningeal involvement in B-cell chronic lymphocytic leukemia: a case report and review of the literature.

Authors:  Simone Lima de Souza; Fábio Santiago; Marilza de Moura Ribeiro-Carvalho; Adriano Arnóbio; Andréa Ribeiro Soares; Maria Helena Ornellas
Journal:  BMC Res Notes       Date:  2014-09-13

7.  Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.

Authors:  Manoj K Kashyap; Deepak Kumar; Harrison Jones; Carlos I Amaya-Chanaga; Michael Y Choi; Johanna Melo-Cardenas; Amine Ale-Ali; Michelle R Kuhne; Peter Sabbatini; Lewis J Cohen; Suresh G Shelat; Laura Z Rassenti; Thomas J Kipps; Pina M Cardarelli; Januario E Castro
Journal:  Oncotarget       Date:  2016-01-19

8.  Evaluation of CD38 expression in Sudanese patients with chronic lymphocytic leukemia.

Authors:  Enaam Abdelrhman Abdelgader; Nada Hassan Eltayeb; Tasniem Ahmed Eltahir; Osama Ali Altayeb; Eman Abbass Fadul; Eldirdiri M Abdel Rahman; Tarig H Merghani
Journal:  BMC Res Notes       Date:  2018-11-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.